Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_assertion type Assertion NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_head.
- NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_assertion description "[Targeted therapy against triple-negative breast cancers, which lack expression of the estrogen, progesterone, and HER2 receptors, is not available and the overall response to cytotoxic chemotherapy is poor.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_provenance.
- NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_assertion evidence source_evidence_literature NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_provenance.
- NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_assertion SIO_000772 24248265 NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_provenance.
- NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_assertion wasDerivedFrom befree-2016 NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_provenance.
- NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_assertion wasGeneratedBy ECO_0000203 NP1129354.RA3Y9GYAckO1TxxncqPvFvdpAchJJFtp1UV93oDXrjrMY130_provenance.